Mizuho analyst Graig Suvannavejh raised the firm’s price target on EyePoint (EYPT) to $33 from $28 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint Pharmaceuticals Raises $141M in Public Offering
- EyePoint reports inducement grants under NASDAQ listing rule
- EyePoint 11M share Spot Secondary priced at $12.00